You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

refractory/relapsed acute myelogenous leukemia

Showing 51 - 75 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Acute Myeloid Leukemia Trial in Minneapolis (ALT-803)

Completed
Has Results
  • Acute Myeloid Leukemia
  • ALT-803
  • Minneapolis, Minnesota
    Masonic Cancer Center at University of Minnesota
Oct 30, 2020

B Precursor Acute Lymphoblastic Leukemia, Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia Trial (Blinatumomab)

Not yet recruiting
  • B Precursor Acute Lymphoblastic Leukemia
  • Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia
  • (no location specified)
Sep 25, 2023

Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse Trial in Miami (Bomedemstat,

Recruiting
  • Acute Myeloid Leukemia
  • +2 more
  • Miami, Florida
    University of Miami
Dec 22, 2022

Acute Myeloid Leukemia, MDS Trial in United States (GLB-001)

Recruiting
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndromes
  • Duarte, California
  • +3 more
Nov 21, 2023

Acute Myeloid Leukemia, High-Risk and Very High-Risk MDS Trial (SGR-2921)

Not yet recruiting
  • Acute Myeloid Leukemia
  • High-Risk and Very High-Risk Myelodysplastic Syndromes
  • (no location specified)
Jul 25, 2023

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous

Recruiting
  • Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 31, 2022

Refractory B-cell Acute Lymphoblastic Leukemia Trial in Houston (Mosunetuzumab)

Not yet recruiting
  • Refractory B-cell Acute Lymphoblastic Leukemia
  • Houston, Texas
    M D Anderson Cancer Center
Jul 18, 2023

Acute Lymphoblastic Leukemia Trial (inotuzumab ozogamicin)

Not yet recruiting
  • Acute Lymphoblastic Leukemia
  • inotuzumab ozogamicin
  • (no location specified)
Jan 6, 2023

Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory, Granulocytic Sarcoma Trial in Winston-Salem (drug,

Not yet recruiting
  • Acute Myeloid Leukemia, in Relapse
  • +2 more
  • CPI 613
  • +3 more
  • Winston-Salem, North Carolina
    Wake Forest Baptist Comprehensive Cancer Center
May 10, 2023

Hematologic Malignancy, Acute Myeloid Leukemia, MDS Trial in Chengdu, Shenzhen (CLL1-CD33 cCAR T cells)

Recruiting
  • Hematologic Malignancy
  • +4 more
  • CLL1-CD33 cCAR T cells
  • Chengdu, China
  • +1 more
May 17, 2021

Acute Myeloid Leukemia Trial in Cincinnati (CIML-NK Cells)

Recruiting
  • Acute Myeloid Leukemia
  • CIML-NK Cells
  • Cincinnati, Ohio
    Cincinnati Children's Hospital Medical Center
Jan 4, 2023

AML, Adult Trial in Hangzhou (CLL1 CAR-NK cell injection)

Recruiting
  • AML, Adult
  • CLL1 CAR-NK cell injection
  • Hangzhou, Zhejiang, China
    Clinical research ethics committee of the first affiliated hospi
Aug 30, 2023

Relapsed/Refractory Higher-Risk Myelodysplastic Syndrome, Relapsed/Refractory Acute Myeloid Leukemia Trial (Magrolimab)

Available
  • Relapsed/Refractory Higher-Risk Myelodysplastic Syndrome
  • Relapsed/Refractory Acute Myeloid Leukemia
  • Magrolimab
  • (no location specified)
Jan 18, 2023

Chronic Myelogenous Leukemia Trial in Houston (TGRX-678)

Not yet recruiting
  • Chronic Myelogenous Leukemia
  • Houston, Texas
    The University of Texas MD Anderson Cancer Center
Oct 12, 2023

Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Trial in China (BL-M11D1)

Not yet recruiting
  • Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
  • Hefei, Anhui, China
  • +7 more
Jun 27, 2023

Relapsed/Refractory Acute Myeloid Leukemia Trial (LILRB4 STAR-T cells)

Not yet recruiting
  • Relapsed/Refractory Acute Myeloid Leukemia
  • LILRB4 STAR-T cells
  • (no location specified)
Sep 16, 2022

Leukemia, Relapsed, Myeloid Trial in Netherlands, Switzerland (MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123

Recruiting
  • Leukemia
  • +3 more
  • MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70)
  • Amsterdam, Netherlands
  • +4 more
Jan 4, 2023

Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial (UAE Inhibitor TAK-243)

Not yet recruiting
  • Myelodysplastic Syndrome
  • +4 more
  • UAE Inhibitor TAK-243
  • (no location specified)
Oct 20, 2022

Acute Myeloid Leukemia Trial in Beijing, Tianjin (LCAR-AMDR Cells Product)

Recruiting
  • Acute Myeloid Leukemia
  • LCAR-AMDR Cells Product
  • Beijing, Beijing, China
  • +1 more
Jan 28, 2023

B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma, Diffuse Large B Cell Lymphoma Trial in Beijing (CD19/CD22-bispecific CAR-T

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • +2 more
  • CD19/CD22-bispecific CAR-T cells
  • Beijing, Beijing, China
    Liang Wang
Oct 7, 2023

Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia Trial in Miami (Pevonedistat, Vincristine,

Completed
  • Refractory Acute Lymphoblastic Leukemia
  • Relapsed Acute Lymphoblastic Leukemia
  • Miami, Florida
    University of Miami
Oct 19, 2022

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute

Active, not recruiting
  • Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
  • +2 more
  • Duarte, California
    City of Hope Medical Center
Jan 4, 2023

Leukemia, Myeloid, Acute Trial (CD33KO-HSPC; CART33)

Not yet recruiting
  • Leukemia, Myeloid, Acute
  • CD33KO-HSPC; CART33
  • (no location specified)
Jul 13, 2023

Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse Trial in Xuzhou (anti-siglec-6 CAR-T cell therapy)

Recruiting
  • Acute Myeloid Leukemia Refractory
  • Acute Myeloid Leukemia, in Relapse
  • anti-siglec-6 CAR-T cell therapy
  • Xuzhou, Jiangsu, China
    Kailin Xu
Aug 2, 2022

AML/MDS, Acute Myeloid Leukemia, MDS Trial (Danvatirsen, Danvatirsen + Venetoclax)

Not yet recruiting
  • AML/MDS
  • +2 more
  • (no location specified)
Aug 14, 2023